ABI-110 for Wet Age-Related Macular Degeneration
Trial Summary
What is the purpose of this trial?
This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it does require a history of anti-VEGF injections, so you may need to continue those treatments.
What data supports the effectiveness of the treatment ABI-110 for Wet Age-Related Macular Degeneration?
What safety data exists for ABI-110 (AAV2.N54-VEGF Trap) in humans?
The safety of treatments similar to ABI-110, like aflibercept and AAV2-sFLT01, has been studied in people with eye conditions like wet age-related macular degeneration. These studies generally show that such treatments are safe for use in the eye, with some patients experiencing mild side effects like eye discomfort or increased eye pressure.16789
How is the treatment ABI-110 different from other treatments for wet age-related macular degeneration?
Eligibility Criteria
This trial is for patients with wet age-related macular degeneration (wAMD), including those with symptomatic macular polypoidal choroidal vasculopathy (PCV). Specific eligibility criteria are not provided, but typically include a confirmed diagnosis and no contraindications for treatment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Confirmation of Response
Confirmation of response to EYLEA (aflibercept) before administration of ABI-110
Treatment
Single administration of ABI-110 (AAV2.N54-VEGF-Trap) injection
Follow-up
Participants are monitored for safety, tolerability, and preliminary efficacy after treatment
Treatment Details
Interventions
- ABI-110
ABI-110 is already approved in United States for the following indications:
- Wet Age-related Macular Degeneration (AMD)
- Polypoidal Choroidal Vasculopathy (PCV)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Avirmax Biopharma Inc
Lead Sponsor